Works in mice? It’s a winner for Homology as IPO reaps $144M haul, with biotech on a roll
Gene editing remains one of the hottest games in biopharma, well before we get to see any human data from clinical trials.
Tuesday evening Bedford …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
